WATCHES OF SWITZERLAND GROUP PLC (the 'Company')
DIRECTOR/PDMR SHAREHOLDING
The following information is given in accordance with Article 19.3 of the Market Abuse Regulation and is made on behalf of Brian Duffy a PDMR, in the Watches of Switzerland Group PLC under article 19.1 of the Market Abuse Regulation ('MAR').
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Brian Duffy | |||
2
| Reason for the notification
| ||||
a)
| Position/status | Chief Executive Officer | |||
b)
| Initial notification /Amendment
| Initial | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name | Watches of Switzerland Group PLC | |||
b)
| LEI | 2138008ZOT5K9PJW7168 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.0125 each | |||
| | ||||
Identification code | GB00BJDQQ870 | ||||
| | ||||
b)
| Nature of the transaction
| An award of deferred shares granted on 20 July 2023 under the Company's 2019 Annual and Deferred Bonus Plan. The shares will be deferred for a period of three years from the date of grant.
| |||
c)
| Price(s) and volume(s) | | | | |
| | Price(s) | Volume(s) | | |
| | £7.56 | 24,801 | | |
| | | | | |
d)
| Aggregated information | | |||
| | ||||
- Aggregated volume | 24,801 | ||||
| | ||||
- Price | £187,496 | ||||
| | ||||
e)
| Date of the transaction
| 20 July 2023 | |||
f)
| Place of the transaction
| XLON |
Enquiries:
Laura Battley Lucy Legh / Rob Walker / Joanna Clark
Company Secretary and General Counsel Headland
T: 0207 317 4604 T: 0203 805 4822
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.